These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26303222)

  • 21. Initiation of Monthly Minodronate Therapy at an Early Stage After Hip Fracture.
    Ohishi T; Fujita T; Suzuki D; Nishida T; Okabayashi R; Yamamoto K; Ushirozako H; Banno T; Matsuyama Y
    J Clin Densitom; 2016; 19(3):352-8. PubMed ID: 27067298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.
    Hasegawa E; Ito S; Takai C; Kobayashi D; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
    Intern Med; 2018 Aug; 57(15):2169-2178. PubMed ID: 29607978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination treatment with eldecalcitol (ED-71) and raloxifene improves bone mechanical strength by suppressing bone turnover and increasing bone mineral density in ovariectomized rats.
    Takeda S; Sakai S; Shiraishi A; Koike N; Mihara M; Endo K
    Bone; 2013 Mar; 53(1):167-73. PubMed ID: 23232307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study.
    Soen S; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Ito M; Nakano T; Hagino H; Hirakawa A; Matsumoto T
    J Bone Miner Metab; 2020 Jul; 38(4):511-521. PubMed ID: 31970477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients.
    Suzuki T; Nakamura Y; Kato H
    Nutrients; 2018 Feb; 10(3):. PubMed ID: 29495518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
    Hakala M; Kröger H; Valleala H; Hienonen-Kempas T; Lehtonen-Veromaa M; Heikkinen J; Tuomiranta T; Hannonen P; Paimela L;
    Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis.
    Igase M; Kohara K; Tabara Y; Ohara M; Takita R; Ochi M; Okada Y; Miki T
    Menopause; 2014 Sep; 21(9):962-6. PubMed ID: 24552979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential association with early changes in serum calcium level after starting or switching to denosumab combined with eldecalcitol.
    Asano T; Shimizu T; Takahashi D; Ota M; Sato D; Hamano H; Hiratsuka S; Takahata M; Iwasaki N
    J Bone Miner Metab; 2019 Mar; 37(2):351-357. PubMed ID: 29721807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study.
    Kobayashi M; Sawada K; Yoshimura A; Yamamoto M; Shimizu A; Shimura K; Komura N; Miyamoto M; Ishida K; Kimura T
    BMC Womens Health; 2020 Mar; 20(1):48. PubMed ID: 32138724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (PROMADE) study.
    Yoshida T; Kinoshita H; Taniguchi H; Yanishi M; Sugi M; Matsuda T
    Osteoporos Int; 2020 Jul; 31(7):1251-1259. PubMed ID: 31993719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of risedronate, alendronate, and minodronate alone or in combination with eldecalcitol on bone mineral density, quality, and strength in ovariectomized rats.
    Yano T; Ito T; Kanehira Y; Yamada M; Kimura-Suda H; Wagatsuma H; Inoue D
    Bone Rep; 2021 Jun; 14():101061. PubMed ID: 33898659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
    Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T
    Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of minodronate and activated vitamin D on bone mineral density and muscle mass in postmenopausal women with osteoporosis.
    Fujimoto K; Inage K; Toyoguchi T; Eguchi Y; Orita S; Yamauchi K; Suzuki M; Kubota G; Sainoh T; Sato J; Shiga Y; Abe K; Kanamoto H; Inoue M; Kinoshita H; Norimoto M; Umimura T; Koda M; Furuya T; Nakamura J; Akazawa T; Terakado A; Takahashi K; Ohtori S
    Spine Surg Relat Res; 2018; 2(2):148-153. PubMed ID: 31440661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence on the bone mineral density and bone metabolism marker after the interruption and reinitiation of monthly minodronate therapy in postmenopausal women with osteoporosis.
    Okimoto N; Arita S; Akahoshi S; Baba K; Fukuhara S; Ishikura T; Yoshioka T; Fuse Y; Okamoto K; Menuki K; Sakai A
    Osteoporos Sarcopenia; 2018 Jun; 4(2):61-68. PubMed ID: 30775544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of daily teriparatide treatment for osteoporosis in men.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
    Osteoporos Int; 2015 Apr; 26(4):1303-9. PubMed ID: 25567777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.